GTC Biotherapeutics (fka GTCB)

[croumagnon]

GTCB has now become a tax loss stock

I am glad I sold half my holdings at the $1.23 level because I fear that downside will compound further downside as GTCB may now have become a tax loss stock for 2006. I am holding the rest for the ride, and I may add more if it drops below $1 or as we approach year-end.

Long-term, this is still agreat buy and hold and I think there is very litle risk at these prices given the ATryn approval in the EU. Frankly, I am greatly disappointed by the recent performance of this stock as I thought for sure we will see prices well past $2 following the EU approval. The company is waayyy undervalued currently but the excitement has left the stock and the latest low-priced deal has taken the winds out of our sail for a while...